Detalles de la búsqueda
1.
The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
Breast Cancer Res Treat;
118(2): 323-31, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19011961
2.
Spiro(imidazo[1,2-a]pyrano[2,3-c]pyridine-9-indenes) as inhibitors of gastric acid secretion.
Bioorg Med Chem;
17(1): 368-84, 2009 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19026549
3.
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
JAMA;
302(13): 1429-36, 2009 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-19809024
4.
Variational data assimilation for transient blood flow simulations: Cerebral aneurysms as an illustrative example.
Int J Numer Method Biomed Eng;
35(1): e3152, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30198152
5.
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
BMC Cancer;
8: 364, 2008 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-19077243
6.
5-Substituted 1H-pyrrolo[3,2-b]pyridines as inhibitors of gastric acid secretion.
Bioorg Med Chem;
16(3): 1511-30, 2008 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17962023
7.
Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
Bioorg Med Chem;
16(1): 536-41, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17964794
8.
Synthesis and evaluation of 7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridines as potassium-competitive acid blockers.
J Med Chem;
50(24): 6240-64, 2007 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-17975907
9.
Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer.
Anticancer Res;
27(4B): 2131-9, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17695496
10.
Preparation of tetrahydroimidazo[2,1-a]isoquinolines and their use as inhibitors of gastric acid secretion.
Bioorg Med Chem;
15(24): 7647-60, 2007 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17881235
11.
Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study.
Onkologie;
30(8-9): 443-9, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17848816
12.
Hydroxyl radical scavenging reactivity of proton pump inhibitors.
Biochem Pharmacol;
71(9): 1337-41, 2006 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-16494850
13.
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
BMC Cancer;
6: 86, 2006 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16603054
14.
c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
Breast Cancer Res;
7(3): R374-84, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15987433
15.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Breast Care (Basel);
7(4): 289-95, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23904831
16.
Effects of pantoprazole in experimental acute pancreatitis.
Life Sci;
87(17-18): 551-7, 2010 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-20851132
17.
Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel.
J Med Chem;
53(9): 3645-74, 2010 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20380432
18.
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Cancer Res;
68(23): 9799-808, 2008 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19047159
19.
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
J Clin Oncol;
25(33): 5187-93, 2007 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-18024866
20.
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Pharmacogenet Genomics;
17(7): 529-38, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17558308